IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY. (12th June 2019) - Wu, J.; Bolen, C.; Seymour, J.F.; Hillmen, P.; Eichhorst, B.; Eldering, E.; Kipps, T.J.; Langerak, A.W.; Mellink, C.; van der Kevie‐Kersemaekers, A.F.; Owen, C.; Chyla, B.; et al.